Résumé
Dans un contexte où la résistance aux antibiotiques est un phénomène de plus en plus préoccupant, une analyse systématique des autres options thérapeutiques semble fondamentale en pathologie infectieuse. Les anticorps polypuis monoclonaux représentent une piste thérapeutique majeure avec le développement d’anticorps dirigés contre les systèmes de virulence spécifiques de certains pathogènes. La modulation du quorum-sensing et des facteurs de virulence en dépendant est une approche en plein développement en pathologie aiguë comme dans les infections chroniques. Enfin, les bactériophages ou les probiotiques peuvent aussi constituer une solution de recours dans divers tableaux infectieux. Cette revue précise les avancées dans chacun de ces domaines de la thérapeutique anti-infectieuse non antibiotique.
Abstract
Given the preoccupying increase of antimicrobial resistance, a systematic review of alternative therapeutic options seems necessary for anyone involved in managing infectious diseases. Both polyconal and monoclonal antibodies represent a major alternative to conventional antimicrobials, especially when considering the development of monoclonal antibodies against specific bacterial virulence factors. Modulating the expression of virulence factors by interfering with quorum-sensing systems is another major emerging approach to both acute and chronic infections. Finally, phage therapy and probiotics may also be considered as additional alternatives or adjuncts to antimicrobial therapy. This review presents a brief overview of the recent advances in the fields of non-antibiotic antimicrobial therapy.
Article PDF
Références
Casadevall A, Scharff MD (1995) Return to the past: the case for antibody-based therapies in infectious diseases. Clin Infect Dis 21:150–161
Kaufmann SH (2007) The contribution of immunology to the rational design of novel antibacterial vaccines. Nat Rev Microbiol 5:491–504
LaRocca TJ, Katona LI, Thanassi DG, Benach JL (2008) Bactericidal action of a complement-independent antibody against relapsing fever Borrelia resides in its variable region. J Immunol 180:6222–6228
Casadevall A, Pirofski LA (2003) Antibody-mediated regulation of cellular immunity and the inflammatory response. Trends Immunol 24:474–478
Dethlefsen L, McFall-Ngai M, Relman DA (2007) An ecological and evolutionary perspective on human-microbe mutualism and disease. Nature 449:811–818
Beaugerie L, Petit JC (2004) Microbial-gut interactions in health and disease. Antibiotic-associated diarrhoea. Best Pract Res Clin Gastroenterol 18:337–352
Marra F, Lynd L, Coombes M, et al (2006) Does antibiotic exposure during infancy lead to development of asthma? A systematic review and metaanalysis. Chest 129:610–618
Taborda CP, Rivera J, Zaragoza O, Casadevall A (2003) More is not necessarily better: prozone-like effects in passive immunization with IgG. J Immunol 170:3621–3630
Akiyama M, Oishi K, Tao M, et al (2000) Antibacterial properties of Pseudomonas aeruginosa immunotype 1 lipopolysaccharidespecific monoclonal antibody (MAb) in a murine thigh infection model: combined effects of MAb and ceftazidime. Microbiol Immunol 44:629–635
Froude JW, Stiles B, Pelat T, Thullier P (2011) Antibodies for biodefense. MAbs 3:517–527
Schneemann A, Manchester M (2009) Anti-toxin antibodies in prophylaxis and treatment of inhalation anthrax. Future Microbiol 4:35–43
Plotkin S, Grabenstein JD (2008) Countering anthrax: Vaccines and immunoglobulins. Clin Infect Dis 46:129–136
Kulshreshtha P, Bhatnagar R (2011) Inhibition of anthrax toxins with a bispecific monoclonal antibody that cross reacts with edema factor as well as lethal factor of Bacillus anthracis. Mol Immunol 48:1958–1965
Bitzan M (2009) Treatment options for HUS secondary to Escherichia coli O157:H7. Kidney Int 75:S62–S66
Bitzan M, Poole R, Mehran M, et al (2009) Safety and pharmacokinetics of chimeric anti-Shiga toxin 1 and anti-Shiga toxin 2 monoclonal antibodies in healthy volunteers. Antimicrob Agents Chemother 53:3081–3087
Dowling TC, Chavaillaz PA, Young DG, et al (2005) Phase 1 safety and pharmacokinetic study of chimeric murine-human monoclonal antibody c Stx2 administered intravenously to healthy adult volunteers. Antimicrob Agents Chemother 49:1808–1812
Lapeyraque AL, Malina M, Fremeaux-Bacchi V, et al (2011) Eculizumab in severe Shiga-toxin-associated HUS. N Engl J Med 364:2561–2563
Lowy I, Molrine DC, Leav BA, et al (2010) Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 362:197–205
Weisman LE, Fischer GW, Thackray HM, et al (2009) Safety and pharmacokinetics of a chimerized anti-lipoteichoic acid monoclonal antibody in healthy adults. Int Immunopharmacol 9:639–644
Weisman L, Thackray H, Steinhorn R (2011) A randomized study of a monoclonal antibody (pagibaximab) to prevent staphylococcal sepsis. Pediatrics 128:271–279
Hetherington S, Texter M, Wenzel E, et al (2006) Phase I dose escalation study to evaluate the safety and pharmacokinetic profile of tefibazumab in subjects with end-stage renal disease requiring hemodialysis. Antimicrob Agents Chemother 50:3499–500
Weems JJ, Steinberg JP, Filler S, et al (2006) Phase II, randomized, double-blind, multicenter study comparing the safety and pharmacokinetics of tefibazumab to placebo for treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 50:2751–2755
Benjamin DK, Schelonka R, White R, et al (2006) A blinded, randomized, multicenter study of an intravenous Staphylococcus aureus immune globulin. J Perinatol 26:290–295
Rupp ME, Holley HP, Lutz J, et al (2007) Phase II, randomized, multicenter, double-blind, placebo-controlled trial of a polyclonal anti-Staphylococcus aureus capsular polysaccharide immune globulin in treatment of Staphylococcus aureus bacteremia. Antimicrob Agents Chemother 51:4249–4254
Ragle BE, Bubeck Wardenburg J (2009) Anti-alpha-hemolysin monoclonal antibodies mediate protection against Staphylococcus aureus pneumonia. Infect Immun 77:2712–2718
LeClaire RD, Hunt RE, Bavari S (2002) Protection against bacterial superantigen staphylococcal enterotoxin B by passive vaccination. Infect Immun 70:2278–2281
Larsen RA, Pappas PG, Perfect J, et al (2005) Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7 in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49:952–958
Matthews R, Rigg G, Hodgetts S (2003) Preclinical assessment of the efficacy of mycograb, a human recombinant antibody against fungal HSP90. Antimicrobial Agents Chemother 47:2208–2216
Matthews RC, Burnie JP, Tabaqchali S (1987) Isolation of immunodominant antigens from sera of patients with systemic candidiasis and characterization of serological response to Candida albicans. J Clin Microbiol 25:230–237
Kaufmann GF, Park J, Janda KD (2008) Bacterial quorum sensing: a new target for anti-infective immunotherapy. Expert Opin Biol Ther 8:719–724
Park J, Jagasia R, Kaufmann GF, et al (2007) Infection control by antibody disruption of bacterial quorum sensing signaling. Chem Biol 14:1119–1127
Jones RN (2010) Microbial etiologies of hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia. Clin Infect Dis 51(S1):S81–S87
Kipnis E, Sawa T, Wiener-Kronish J (2006) Targeting mechanisms of Pseudomonas aeruginosa pathogenesis. Med Mal Infect 36:78–91
Hauser AR (2009) The type III secretion system of Pseudomonas aeruginosa: infection by injection. Nat Rev Microbiol 7:654–665
Hueck CJ (1998) Type III protein secretion systems in bacterial pathogens of animals and plants. Microbiol Mol Biol Rev 62:379–433
Cornelis GR, Van Gijsegem F (2000) Assembly and function of type III secretory systems. Annu Rev Microbiol 54:735–774
Sawa T, Yahr TL, Ohara M, et al (1999) Active and passive immunization with the Pseudomonas V antigen protects against type III intoxication and lung injury. Nat Med 5:392–398
Neely AN, Holder IA, Wiener-Kronish JP, Sawa T (2005) Passive anti-PcrV treatment protects burned mice against Pseudomonas aeruginosa challenge. Burns 31:153–158
Kurahashi K, Kajikawa O, Sawa T, et al (1999) Pathogenesis of septic shock in Pseudomonas aeruginosa pneumonia. J Clin Invest 104:743–750
Allewelt M, Coleman FT, Grout M, et al (2000) Acquisition of expression of the Pseudomonas aeruginosa ExoU cytotoxin leads to increased bacterial virulence in a murine model of acute pneumonia and systemic spread. Infect Immun 68:3998–4004
Ader F, Le Berre R, Faure K, et al (2005) Alveolar response to Pseudomonas aeruginosa: role of the type III secretion system. Infect Immun 73:4263–4271
Roy-Burman A, Savel RH, Racine S, et al (2001) Type III protein secretion is associated with death in lower respiratory and systemic Pseudomonas aeruginosa infections. J Infect Dis 183:1767–1774
Hauser AR, Cobb E, Bodi M, et al (2002) Type III protein secretion is associated with poor clinical outcomes in patients with ventilator-associated pneumonia caused by Pseudomonas aeruginosa. Crit Care Med 30:521–528
Shaver CM, Hauser AR (2004) Relative contributions of Pseudomonas aeruginosa ExoU, ExoS, and ExoT to virulence in the lung. Infect Immun 72:6969–6977
Schulert GS, Feltman H, Rabin SDP, et al (2003) Secretion of the toxin ExoU is a marker for highly virulent Pseudomonas aeruginosa isolates obtained from patients with hospital-acquired pneumonia. J Infect Dis 188:1695–1706
Shime N, Sawa T, Fujimoto J, et al (2001) Therapeutic administration of anti-PcrV F(ab’)(2) in sepsis associated with Pseudomonas aeruginosa. J Immunol 167:5880–5886
Faure K, Fujimoto J, Shimabukuro DW, et al (2003) Effects of monoclonal anti-PcrV antibody on Pseudomonas aeruginosainduced acute lung injury in a rat model. J Immune Based Ther Vaccines 1:2
Frank DW, Vallis A, Wiener-Kronish JP, et al (2002) Generation and characterization of a protective monoclonal antibody to Pseudomonas aeruginosa PcrV. J Infect Dis 186:64–73
Baer M, Sawa T, Flynn P, et al (2009) An engineered human antibody fab fragment specific for Pseudomonas aeruginosa PcrV antigen has potent antibacterial activity. Infect Immun 77:1083–1090
Chastre J, Dugard A, Luyt CE, et al (2010) A Pilot Study Of The Humaneered TM Anti-PcrV Monoclonal Antibody, KB001., in Mechanically-Ventilated (MV) Subjects Colonized With Pseudomonas Aeruginosa (Pa). Am J Respir Crit Care Med 181:A2274 EP
Lazar H, Horn MP, Zuercher AW, et al (2009) Pharmacokinetics and Safety Profile of the Human Anti-Pseudomonas aeruginosa Serotype O11 Immunoglobulin M Monoclonal Antibody KBPA-101 in Healthy Volunteers. Antimicrob Agents Chemother 53:3442–3446
Nooney L, Matthews RC, Burnie JP (2005) Evaluation of Mycograb ®, amphotericin B, caspofungin, and fluconazole in combination against Cryptococcus neoformans by checkerboard and timekill methodologies. Diagn Microbiol Infect Dis 51:19–29
Pachl J, Svoboda P, Jacobs F, et al (2006) A randomized, blinded, multicenter trial of lipid-associated amphotericin B alone versus in combination with an antibody-based inhibitor of heat shock protein 90 in patients with invasive candidiasis. Clin Infect Dis 42:1404–1413
Song Y, Baer M, Srinivasan R, Lima J, et al (2011) PcrV antibody-antibiotic combination improves survival in Pseudomonas aeruginosa-infected mice. Eur J Clin Microbiol Infect Dis 2011 [In press]
Al-Hamad A, Burnie J, Upton M (2011) Enhancement of antibiotic susceptibility of Stenotrophomonas maltophilia using a polyclonal antibody developed against an ABC multidrug efflux pump. Can J Microbiol 57:820–828
Lindorfer MA, Nardin A, Foley PL, et al (2001) Targeting of Pseudomonas aeruginosa in the bloodstream with bispecific monoclonal antibodies. J Immunol 167:2240–2249
Mohamed N, Clagett M, Li J, Jet al (2005) A high-affinity monoclonal antibody to anthrax protective antigen passively protects rabbits before and after aerosolized Bacillus anthracis spore challenge. Infect Immun 73:795–802
Gyimesi E, Bankovich AJ, Schuman TA, et al (2004) Staphylococcus aureus bound to complement receptor 1 on human erythrocytes by bispecific monoclonal antibodies is phagocytosed by acceptor macrophages. Immunol Lett 95:185–192
Lai Z, Kimmel R, Petersen S, et al (2005) Multi-valent human monoclonal antibody preparation against Pseudomonas aeruginosa derived from transgenic mice containing human immunoglobulin loci is protective against fatal pseudomonas sepsis caused by multiple serotypes. Vaccine 23:3264–3271
Nowakowski A (2002) Potent neutralization of botulinum neurotoxin by recombinant oligoclonal antibody. Proc Natl Acad Sci U S A 99:11346–11350
Dadachova E (2003) Ionizing radiation delivered by specific antibody is therapeutic against a fungal infection. Proc Natl Acad Sci USA 100:10942–10947
Dadachova E, Howell RW, Bryan RA, et al (2004) Susceptibility of the human pathogenic fungi Cryptococcus neoformans and Histoplasma capsulatum to gamma-radiation versus radioimmunotherapy with alpha- and beta-emitting radioisotopes. J Nucl Med 45:313–320
Dadachova E, Burns T, Bryan RA, et al (2004) Feasibility of radioimmunotherapy of experimental pneumococcal infection. Antimicrob Agents Chemother 48:1624–1629
Antunes LC, Ferreira RB, Buckner MM, Finlay BB (2010) Quorum sensing in bacterial virulence. Microbiology 156:2271–2282
Cirioni O, Ghiselli R, Minardi D, et al (2007) RNAIII-inhibiting peptide affects biofilm formation in a rat model of staphylococcal ureteral stent infection. Antimicrob Agents Chemother 51:4518–4520
Le Berre R, Nguyen S, Nowak E, et al (2008) Quorum-sensing activity and related virulence factor expression in clinically pathogenic isolates of Pseudomonas aeruginosa. Clin Microbiol Infect 14:337–343
Amara N, Krom BP, Kaufmann GF, Meijler MM (2011) Macromolecular inhibition of quorum sensing: enzymes, antibodies, and beyond. Chem Rev 111:195–208
Cushnie TP, Lamb AJ (2011) Recent advances in understanding the antibacterial properties of flavonoids. Int J Antimicrob Agents 38:99–107
Smyth AR, Cifelli PM, Ortori CA, et al (2010) Garlic as an inhibitor of Pseudomonas aeruginosa quorum sensing in cystic fibrosis-a pilot randomized controlled trial. Pediatr Pulmonol 45:356–362
Deresinski S (2009) Bacteriophage therapy: exploiting smaller fleas. Clin Infect Dis 48:1096–1101
O’Flaherty S, Ross RP, Coffey A (2009) Bacteriophage and their lysins for elimination of infectious bacteria. FEMS Microbiol Rev 33:801–819
Sulakvelidze A, Alavidze Z, Morris JG (2001) Bacteriophage therapy. Antimicrob Agents Chemother 45:649–659
Harper DR, Enright MC (2011) Bacteriophages for the treatment of Pseudomonas aeruginosa infections. J Appl Microbiol 111:1–7
Lu TK, Koeris MS (2011) The next generation of bacteriophage therapy. Curr Opin Microbiol 14:524–531
Ryan EM, Gorman SP, Donnelly RF, Gilmore BF (2011) Recent advances in bacteriophage therapy: how delivery routes, formulation, concentration and timing influence the success of phage therapy. J Pharm Pharmacol 63:1253–1264
Kutateladze M, Adamia R (2008) Phage therapy experience at the Eliava Institute. Med Mal Infect 38:426–430
Slopek S, Weber-Dabrowska B, Dabrowski M, Kucharewicz-Krukowska A (1987) Results of bacteriophage treatment of suppurative bacterial infections in the years 1981-1986. Arch Immunol Ther Exp (Warsz) 35:569–583
Weber-Dabrowska B, Mulczyk M, Górski A (2000) Bacteriophage therapy of bacterial infections: an update of our institute’s experience. Arch Immunol Ther Exp (Warsz) 48:547–551
Cisło M, Dabrowski M, Weber-Dabrowska B, Woytoń A (1987) Bacteriophage treatment of suppurative skin infections. Arch Immunol Ther Exp (Warsz) 35:175–183
Weber-Dabrowska B, Mulczyk M, Górski A (2003) Bacteriophages as an efficient therapy for antibiotic-resistant septicemia in man. Transplant Proc 35:1385–1386
Rhoads DD, Wolcott RD, Kuskowski MA, et al (2009) Bacteriophage therapy of venous leg ulcers in humans: results of a phase I safety trial. J Wound Care 18:237–238
Wright A, Hawkins CH, Anggård EE, Harper DR (2009) A controlled clinical trial of a therapeutic bacteriophage preparation in chronic otitis due to antibiotic-resistant Pseudomonas aeruginosa; a preliminary report of efficacy. Clin Otolaryngol 34:349–357
Rolain JM, Fancello L, Desnues C, Raoult D (2011) Bacteriophages as vehicles of the resistome in cystic fibrosis. J Antimicrob Chemother 66:2444–2447
Mahony J, McAuliffe O, Ross RP, van Sinderen D (2011) Bacteriophages as biocontrol agents of food pathogens. Curr Opin Biotechnol 22:157–163
WHO F. Guidelines for the Evaluation of Probiotics in Food. 30AD
Yan F, Polk DB (2010) Probiotics: progress toward novel therapies for intestinal diseases. Curr Opin Gastroenterol 26:95–101
Ghosh S, van Heel D, Playford RJ (2004) Probiotics in inflammatory bowel disease: is it all gut flora modulation? Gut 53:620–622
Isolauri E (2001) Probiotics in human disease. Am J Clin Nutr 73:1142S–1146S
Majamaa H, Isolauri E (1997) Probiotics: a novel approach in the management of food allergy. J Allergy Clin Immunol 99:179–185
Zamfir M, Callewaert R, Cornea, PC, et al (1999) Purification and characterization of a bacteriocin produced by Lactobacillus acidophilus IBB 801. J Appl Microbiol 87:923–931
Aiba Y, Suzuki N, Kabir AM, et al (1998) Lactic acid-mediated suppression of Helicobacter pylori by the oral administration of Lactobacillus salivarius as a probiotic in a gnotobiotic murine model. Am J Gastroenterol 93:2097–2101
Akisu M, Baka M, Yalaz M, et al (2003) Supplementation with Saccharomyces boulardii ameliorates hypoxia/reoxygenation-induced necrotizing enterocolitis in young mice. Eur J Pediatr Surg 13:319–323
Otte JM, Podolsky DK (2004) Functional modulation of enterocytes by gram-positive and gram-negative microorganisms. Am J Physiol Gastrointest Liver Physiol 286:G613–G626
Gionchetti P, Lammers KM, Rizzello F, Campieri M (2005) Probiotics and barrier function in colitis. Gut 54:898–900
Bernet MF, Brassart D, Neeser JR, Servin AL (1994) Lactobacillus acidophilus LA 1 binds to cultured human intestinal cell lines and inhibits cell attachment and cell invasion by enterovirulent bacteria. Gut 35:483–489
Paton AW, Jennings MP, Morona R, et al (2005) Recombinant probiotics for treatment and prevention of enterotoxigenic Escherichia coli diarrhea. Gastroenterology 128:1219–1228
Hickson M, D’souza AL, Muthu N, et al (2007) Use of probiotic Lactobacillus preparation to prevent diarrhoea associated with antibiotics: randomised double blind placebo controlled trial. BMJ 335:80
Ohland CL, Macnaughton WK (2010) Probiotic bacteria and intestinal epithelial barrier function. Am J Physiol Gastrointest Liver Physiol 298:G807–G819
Walker WA (2008) Mechanisms of action of probiotics. Clin Infect Dis 46(Suppl 2):S87–S91
Manley KJ, Fraenkel MB, Mayall BC, Power DA (2007) Probiotic treatment of vancomycin-resistant enterococci: a randomised controlled trial. Med J Aust 186:454–457
de Regt MJ, Willems RJ, Hene RJ, et al (2010) Effects of probiotics on acquisition and spread of multiresistant enterococci. Antimicrob Agents Chemother 54:2801–2805
Vidal M, Forestier C, Charbonnel N, et al (2010) Probiotics and intestinal colonization by vancomycin-resistant enterococci in mice and humans. J Clin Microbiol 48:2595–2598
Tannock GW, Tiong IS, Priest P, et al (2011) Testing probiotic strain Escherichia coli Nissle 1917 (Mutaflor) for its ability to reduce carriage of multidrug-resistant E. coli by elderly residents in long-term care facilities. J Med Microbiol 60:366–370
Oudhuis GJ, Bergmans DC, Dormans T, et al (2010) Probiotics versus antibiotic decontamination of the digestive tract: infection and mortality. Intensive Care Med 37:110–117
Morrow LE, Kollef MH, Casale TB (2010) Probiotic prophylaxis of ventilator-associated pneumonia: a blinded, randomized, controlled trial. Am J Respir Crit Care Med 182:1058–1064
Siempos, Athanassa Z, Falagas ME (2008) Frequency and predictors of ventilator-associated pneumonia recurrence: a meta-analysis. Shock 30:487–495
Besselink MG, van Santvoort HC, Buskens E, et al (2008) Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 371:651–659
Husni RN, Gordon SM, Washington JA, Longworth DL (1997) Lactobacillus bacteremia and endocarditis: review of 45 cases. Clin Infect Dis 25:1048–1055
Rautio M, Jousimies-Somer H, Kauma H, et al (1999) Liver abscess due to a Lactobacillus rhamnosus strain indistinguishable from L. rhamnosus strain GG. Clin Infect Dis 28:1159–1160
Land MH, Rouster-Stevens K, Woods CR, et al (2005) Lactobacillus sepsis associated with probiotic therapy. Pediatrics 115:178–181
Kunz AN, Noel JM, Fairchok MP (2004) Two cases of Lactobacillus bacteremia during probiotic treatment of short gut syndrome. J Pediatr Gastroenterol Nutr 38:457–458
Jones SD, Fullerton DA, Zamora MR, et al (1994) Transmission of Lactobacillus pneumonia by a transplanted lung. Ann Thorac Surg 58:887–889
Barraud D, Blard C, Hein F, et al (2010) Probiotics in the critically ill patient: a double blind, randomized, placebo-controlled trial. Intensive Care Med 36:1540–1547
van Saene HK, Taylor N, Damjanovic V, Sarginson RE (2008) Microbial gut overgrowth guarantees increased spontaneous mutation leading to polyclonality and antibiotic resistance in the critically ill. Curr Drug Targets 9:419–421
Tuomola E, Crittenden R, Playne M, et al (2001) Quality assurance criteria for probiotic bacteria. Am J Clin Nutr 73(2 Suppl):393S–398S
Clements ML, Levine MM, Ristaino PA, et al (1983) Exogenous lactobacilli fed to man. Their fate and ability to prevent diarrheal disease. Prog Food Nutr Sci 7:29–37
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kipnis, É., Dessein, R., Faure, K. et al. Les thérapeutiques anti-infectieuses non antibiotiques. Réanimation 21, 303–316 (2012). https://doi.org/10.1007/s13546-012-0472-y
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s13546-012-0472-y